Periodontal Disease - Pipeline Assessment and Market Forecasts to 2018

Periodontal Disease - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist’s new report, “Periodontal Disease - Pipeline Assessment and Market Forecasts to 2018” is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector. GlobalData estimated the global periodontal disease therapeutics market to be valued at $1,607m in 2010. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 6.4% and reach $2,638m in 2018. The treatment of periodontal disease is dominated by dental procedures and techniques such as scaling, root planing and surgery. Additionally, the locally applied antibiotics (LAAs) and systemic applied antibiotics are used as adjunctive/ maintenance therapies. The LAAs and systemic antibiotics commonly prescribed for periodontal disease include Periochip (chlorhexidine), Arestin (minocycline), Atridox (doxycycline) and Periostat (low dose doxycycline). During the historical period 2005-2010, a major barrier for the periodontal disease therapeutics market was the limited awareness among the individuals about the disease. Fear of pain during surgery and costs related with the treatment procedures resulted in low treatment rates. However, due to the efforts of National Insitute of Dental and Craniofacial Research and National Institute of Health (NIH), these inhibitions have reduced over the past couple of years, importantly; this trend is likely to continue in the future, thereby resulting in an increase in the treatment rates. Increasing prevalence of the periodontal disease is a major factor for growth of the market, moreover, it is estimated that the prevalence of periodontal disease would continue to increase through the forecast period 2018.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key driver and challenges of the global pneumonia market. Its scope includes -
- Annualized global periodontal disease market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include antibiotics (metronidazole + amoxicillin), KCB-1D (recombinant human fibroblast growth factor).
- Analysis of the current and future market competition in the global periodontal disease market. The key market players covered are Kaken Pharmaceutical, Scil Technology, and Fibrocell.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future periodontal disease market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global periodontal disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global periodontal disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global periodontal disease market landscape? – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Periodontal Disease Therapeutics: Executive Summary 7
2.1 The Periodontal Disease Market is Forecast to Show Growth until 2018 7
2.2 Need for New Therapies with Better Efficacy 9
2.3 Weak Pipeline Consists of Only 11 Molecules 10
3 Periodontal Disease Therapeutics: Introduction 11
3.1 Disease Overview 11
3.2 Etiology and Pathogenesis 12
3.3 Signs and Symptoms 16
3.4 Epidemiology 18
3.5 Socio-econiomic status and quality of life: 19
3.6 Diagnosis 20
3.7 Treatment and Management Pattern: 23
3.8 Referral Pathway 28
3.9 GlobalData Pipeline Report Guidance 28
4 Periodontal Disease Therapeutics: Market Characterization 30
4.1 Periodontal Disease Therapeutics Market Size (2005–2010) – Global 30
4.2 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Global 32
4.3 Periodontal Disease Therapeutics Market Size (2005–2010) – The US 33
4.4 Periodontal Disease Therapeutics Market Forecast (2010–2018) – The US 34
4.5 Periodontal Disease Therapeutics Market Size (2005–2010) – The UK 36
4.6 Periodontal Disease Therapeutics Market Forecast (2010–2018) – The UK 37
4.7 Periodontal Disease Therapeutics Market Size (2005–2010) – France 38
4.8 Periodontal Disease Therapeutics Market Forecast (2010–2018) – France 39
4.9 Periodontal Disease Therapeutics Market Size (2005–2010) – Germany 40
4.10 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Germany 42
4.11 Periodontal Disease Therapeutics Market Size (2005–2010) – Italy 43
4.12 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Italy 44
4.13 Periodontal Disease Therapeutics Market Size (2005–2010) – Spain 45
4.14 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Spain 46
4.15 Periodontal Disease Therapeutics Market Size (2005–2010) – Japan 47
4.16 Periodontal Disease Therapeutics Market Size (2010–2018) – Japan 49
4.17 Drivers and Barriers for the Periodontal Disease Therapeutics Market 50
4.17.1 Drivers for Periodontal Disease Market 50
 Increase in Prevalence 50
4.17.2 Barriers for Periodontal Disease Market 50
4.18 Opportunity and Unmet Need Analysis 51
4.19 Key Takeaway 52
5 Periodontal Disease Therapeutics: Competitive Assessment 53
5.1 Overview 53
5.2 Strategic Competitor Assessment 53
5.3 Product Profiles for the Major Marketed Products in the Periodontal Disease Therapeutics Market 55
5.3.1 Periostat (doxycycline hyclate) 55
5.3.2 Periochip (chlorhexidine gluconate) 56
5.3.3 Arestin (minocycline hydrochloride microspheres) 58
5.3.4 Atridox (doxycycline hyclate 10%) 60
5.4 Key Takeaway 61
6 Periodontal Disease Therapeutics Market: Pipeline Assessment 62
6.1 Overview 62
6.2 Strategic Pipeline Assessment 62
6.3 Periodontal Disease Therapeutics Pipeline – Pipeline by Phases of Development 63
6.3.1 Periodontal Disease Therapeutics – Regulatory Filed Products 63
6.3.2 Periodontal Disease Therapeutics – Phase III Pipeline 64
6.3.3 Periodontal Disease Therapeutics – Phase II Pipeline 64
6.3.4 Periodontal Disease Therapeutics – Discovery and Pre-Clinical Pipeline 64
6.3.5 Technology Trends Analytic Framework 65
6.4 Periodontal Disease Therapeutics Market – Pipeline by Mechanism of Action 68
6.5 Periodontal Disease Therapeutics – Promising Drugs under Clinical Development 69
6.6 Molecule Profile for Promising Drugs under Clinical Development 69
6.6.1 KCB-1D (trafermin, bFGF: Basic fibroblast growth factor) 69
6.7 Key Takeaway 70
7 Periodontal Disease Therapeutics: Clinical Trials Mapping 71
7.1 Clinical Trials by Region/Country (US, EU5 and Japan) 71
7.2 Clinical Trials by Phase 72
7.3 Clinical Trials by Trial Status 73
7.4 Clinical Trials by Sponsors 74
7.5 Top Companies Participating in Periodontal Disease Therapeutics Clinical Trials 76
8 Periodontal Disease Therapeutics: Strategic Assessment 77
8.1 Key Events Impacting the Future Market 77
8.2 Periodontal Disease Therapeutics: Implications for Future Market Competition 78
9 Periodontal Disease Therapeutics: Future Players 79
9.1 Introduction 79
9.2 Company Profiles 80
9.2.1 Kaken Pharmaceutical 80
9.2.2 Scil Technology 82
9.2.3 Fibrocell 83
9.2.4 Other Companies in the Periodontal Disease Therapeutics Market 84
10 Periodontal Disease Therapeutics: Licensing and Partnership Deals 86
11 Periodontal Disease Therapeutics: Appendix 87
11.1 Market Definitions 87
11.2 Abbreviations 87
11.3 Research Methodology 88
11.3.1 Coverage 88
11.3.2 Secondary Research 88
11.3.3 Forecasting 89
11.3.4 Primary Research 90
11.3.5 Expert Panel Validation 91
11.4 Contact Us 91
11.5 Disclaimer 91
11.6 Bibliography 92